Date:July. 8, 2021
Your Name:Ping' an Ding
Manuscript Title:Neoadjuvant intraperitoneal and systemic paclitaxel combined with apatinib and S-1
chemotherapy for conversion therapy in gastric cancer patients with positive exfoliative cytology: a prospective
study
Manuscript number (if known):JGO-21-375

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
_			
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests		
	manda meerests		
Ple	ase summarize the above c	onflict of interest in the fo	ollowing box:
	None.		
	· · · · · · · · · ·		
DI.	assa nlaca an "Y" nevt to the	fallawing statement to i	- dit

Date:July. 8, 2	<u> </u>
Your Name:Peig	ang Yang
Manuscript Title:	_Neoadjuvant intraperitoneal and systemic paclitaxel combined with apatinib and S-1
chemotherapy for co	nversion therapy in gastric cancer patients with positive exfoliative cytology: a prospective
study	
Manuscript number	(if known):JGO-21-375

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

_			
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony	X140110	
	testimony		
7	Support for attending	X None	
	meetings and/or travel		
	3 ,		
8	Patents planned, issued or	X None	
J	pending		
	F0		
0	Dauticination () - Data	V None	
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNOTIC	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	ease summarize the above o	onflict of interest in the fo	ollowing box:
_			
	None.		
L			
Ple	ease place an "X" next to the	e following statement to i	ndicate your agreement:

Date:Ju	ly. 8, 2021
Your Name:_	Yuan Tian_
Manuscript T	itle:Neoadjuvant intraperitoneal and systemic paclitaxel combined with apatinib and S-1
chemotherap	y for conversion therapy in gastric cancer patients with positive exfoliative cytology: a prospective
study	
Manuscript n	umber (if known):JGO-21-375
In the interes	t of transparency, we ask you to disclose all relationships/activities/interests listed below that are

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

_				
5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or educational events			
6	Payment for expert	X None		
U	testimony	XNone		
	созинону		+	
7	Support for attending	X None		
	meetings and/or travel			
8	Patents planned, issued or	X None		
O	pending	^NOTIE	+	
	Perionia		+	
	Deutici II	V N		
9	Participation on a Data	XNone		
	Safety Monitoring Board or Advisory Board			
10	Leadership or fiduciary role	X None		
10	in other board, society,	^_Notie		
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	X None		
12	Receipt of equipment,	X_None		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	X None		
13	financial interests			
Ple	ase summarize the above c	onflict of interest in the fo	llowing box:	
	None.			
Ple	ase place an "X" next to the	e following statement to in	ndicate your agreement:	

Date:July. 8, 2021
Your Name: <u>Honghai Guo</u>
Manuscript Title:Neoadjuvant intraperitoneal and systemic paclitaxel combined with apatinib and S-1
chemotherapy for conversion therapy in gastric cancer patients with positive exfoliative cytology: a prospective
study
Manuscript number (if known):JGO-21-375

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

_				
5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or educational events			
6	Payment for expert	X None		
U	testimony	XNone		
	созинону		+	
7	Support for attending	X None		
	meetings and/or travel			
8	Patents planned, issued or	X None		
O	pending	^_NOTIE	+	
	Perionia		+	
	Deutici II	V N		
9	Participation on a Data	XNone		
	Safety Monitoring Board or Advisory Board			
10	Leadership or fiduciary role	X None		
10	in other board, society,	^_Notie		
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	X None		
12	Receipt of equipment,	X_None		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	X None		
13	financial interests			
Ple	ase summarize the above c	onflict of interest in the fo	llowing box:	
	None.			
Ple	ase place an "X" next to the	e following statement to in	ndicate your agreement:	

Date:July. 8, 2021
Your Name:Yang Liu_
Manuscript Title:Neoadjuvant intraperitoneal and systemic paclitaxel combined with apatinib and S-1
chemotherapy for conversion therapy in gastric cancer patients with positive exfoliative cytology: a prospective
study
Manuscript number (if known):JGO-21-375
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third

related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

_			
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
U	testimony	XNone	
	созинону		+
7	Support for attending	X None	
	meetings and/or travel		
8	Patents planned, issued or	X None	
O	pending	^_NOTIE	+
	Perionia		+
	Deutici II	V N	
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	^_Notie	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests		
Ple	ase summarize the above c	onflict of interest in the fo	llowing box:
			1
	None.		
Ple	ase place an "X" next to the	e following statement to in	ndicate your agreement:

	1011152 51502		
Date:July. 8, 2021			
Your Name:Ze Zhang_			
Manuscript Title:Neoadjuv	ant intraperitoneal and	systemic paclitaxel combined with apatinib and S-1	
chemotherapy for conversion the	erapy in gastric cancer pa	atients with positive exfoliative cytology: a prospective	
study			
Manuscript number (if known):_	JGO-21-375		
related to the content of your maparties whose interests may be a to transparency and does not neerelationship/activity/interest, it is	anuscript. "Related" mean iffected by the content on cessarily indicate a bias. is preferable that you do	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third if the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so. ps/activities/interests as they relate to the current	
to the epidemiology of hypertens medication, even if that medicat	sion, you should declare ion is not mentioned in to ort for the work reported	defined broadly. For example, if your manuscript pertai all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other ite	⁄e
	lame all entities with	Specifications/Comments	
	vhom you have this elationship or indicate	(e.g., if payments were made to you or to your institution)	
	none (add rows as	institution)	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

_			
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony	X140110	
	testimony		
7	Support for attending	X None	
	meetings and/or travel		
	3 ,		
8	Patents planned, issued or	X None	
J	pending		
	F0		
0	Dauticination () - Data	V None	
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNOTIC	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	ease summarize the above o	onflict of interest in the fo	ollowing box:
_			
	None.		
L			
Ple	ease place an "X" next to the	e following statement to i	ndicate your agreement:

Date:July. 8, 2021
Your Name:Tao Zheng_
Manuscript Title:Neoadjuvant intraperitoneal and systemic paclitaxel combined with apatinib and S-1
chemotherapy for conversion therapy in gastric cancer patients with positive exfoliative cytology: a prospective
study
Manuscript number (if known):JGO-21-375
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are
related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third
parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment
to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a
relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

_			
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
U	testimony	XNone	
	созинону		+
7	Support for attending	X None	
	meetings and/or travel		
8	Patents planned, issued or	X None	
O	pending	^_NOTIE	+
	Perionia		+
	Deutici II	V N	
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	^_Notie	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests		
Ple	ase summarize the above c	onflict of interest in the fo	llowing box:
			1
	None.		
Ple	ase place an "X" next to the	e following statement to in	ndicate your agreement:

Date:July. 8, 2021
Your Name:Bibo Tan_
Manuscript Title: Neoadjuvant intraperitoneal and systemic paclitaxel combined with apatinib and S-1
chemotherapy for conversion therapy in gastric cancer patients with positive exfoliative cytology: a prospective
study
Manuscript number (if known): JGO-21-375
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

_			
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony	X140116	
	testimony		
7	Support for attending	X None	
	meetings and/or travel		
	3 ,		
8	Patents planned, issued or	X None	
J	pending		
	F0		
0	Dauticination () - Data	V None	
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNOTIC	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	ease summarize the above o	onflict of interest in the fo	ollowing box:
_			
	None.		
L			
Ple	ease place an "X" next to the	e following statement to i	ndicate your agreement:

Da	te:July. 8, 2021					
Your Name: Zhidong Zhang_						
Manuscript Title:Neoadjuvant intraperitoneal and systemic paclitaxel combined with apatinib and S-1						
che	chemotherapy for conversion therapy in gastric cancer patients with positive exfoliative cytology: a prospective					
stu	ıdy					
Ma	nuscript number (if known)	:JGO-21-375				
rela par to	ated to the content of your rties whose interests may be	manuscript. "Related" me e affected by the content on necessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a o so.			
	e following questions apply inuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>			
The			defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive			
to	edication, even if that medic	· ·	-	'e		
to to to me	edication, even if that medic	ation is not mentioned in	-			
to to to me	edication, even if that medic	ation is not mentioned in pport for the work reporte s the past 36 months.	the manuscript.			
to to to me	edication, even if that medic	ation is not mentioned in	the manuscript.			
to to to me	edication, even if that medic	pport for the work reporters the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as	sthe manuscript. In this manuscript without time limit. For all other items Specifications/Comments (e.g., if payments were made to you or to your institution)			
to me	edication, even if that medic item #1 below, report all su e time frame for disclosure i	pport for the work reporters the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	sthe manuscript. In this manuscript without time limit. For all other items Specifications/Comments (e.g., if payments were made to you or to your institution)			
to to to me	edication, even if that medication, even if that medicate #1 below, report all supertime frame for disclosure is	pport for the work reporters the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed)	sthe manuscript. In this manuscript without time limit. For all other items Specifications/Comments (e.g., if payments were made to you or to your institution)			
to me	edication, even if that medication, even if that medicate #1 below, report all support in the frame for disclosure in the frame for disclosure in the frame for the present manuscript (e.g., funding,	pport for the work reporters the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	sthe manuscript. In this manuscript without time limit. For all other items Specifications/Comments (e.g., if payments were made to you or to your institution)			
to me	All support for the present manuscript (e.g., funding, provision of study materials,	pport for the work reporters the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	sthe manuscript. In this manuscript without time limit. For all other items Specifications/Comments (e.g., if payments were made to you or to your institution)			
to me	edication, even if that medication, even if that medicate #1 below, report all support in the frame for disclosure in the frame for disclosure in the frame for the present manuscript (e.g., funding,	pport for the work reporters the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	sthe manuscript. In this manuscript without time limit. For all other items Specifications/Comments (e.g., if payments were made to you or to your institution)			
to me	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	pport for the work reporters the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	sthe manuscript. In this manuscript without time limit. For all other items Specifications/Comments (e.g., if payments were made to you or to your institution)			
to me	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	pport for the work reporters the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	sthe manuscript. In this manuscript without time limit. For all other items Specifications/Comments (e.g., if payments were made to you or to your institution)			
to me	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	pport for the work reporters the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	sthe manuscript. In this manuscript without time limit. For all other items Specifications/Comments (e.g., if payments were made to you or to your institution)			
to me	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	pport for the work reporters the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	sthe manuscript. In this manuscript without time limit. For all other items Specifications/Comments (e.g., if payments were made to you or to your institution) I planning of the work			

Grants or contracts from

in item #1 above).
Royalties or licenses

Consulting fees

3

4

any entity (if not indicated

X__None

X__None

_X__None

_			
5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
U	testimony	XNone	
	созинону		+
7	Support for attending	X None	
	meetings and/or travel		
8	Patents planned, issued or	X None	
O	pending	^NOTIE	+
	Perionia		+
	Deutici II	V N	
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	^_Notie	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	2000. St Stock options		
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests		
			1
Ple	ease summarize the above c	onflict of interest in the fo	llowing box:
_			
	None.		
Ple	ease place an "X" next to the	e following statement to in	ndicate your agreement:

Date:July. 8, 2021
our Name: Dong Wang_
Manuscript Title: Neoadjuvant intraperitoneal and systemic paclitaxel combined with apatinib and S-1
hemotherapy for conversion therapy in gastric cancer patients with positive exfoliative cytology: a prospective
tudy
Manuscript number (if known):JGO-21-375
u the interest of transporter, we get you to displace all relationships (estivities (interests listed helps, that are

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

_			
5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
U	testimony	XNone	
	созинону		+
7	Support for attending	X None	
	meetings and/or travel		
8	Patents planned, issued or	X None	
O	pending	^_NOTIE	+
	Perionis		+
	Deutici II	V N	
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	^_Notie	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	2000. St Stock options		
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests		
			1
Ple	ease summarize the above c	onflict of interest in the fo	llowing box:
_			
	None.		
Ple	ease place an "X" next to the	e following statement to in	ndicate your agreement:

Date:July. 8, 2021
Your Name: Yong Li_
Manuscript Title:Neoadjuvant intraperitoneal and systemic paclitaxel combined with apatinib and S-1
chemotherapy for conversion therapy in gastric cancer patients with positive exfoliative cytology: a prospective
study
Manuscript number (if known):JGO-21-375
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are
related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third
narties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment

parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

_			
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
	testimony		
7	Support for attending	X None	
	meetings and/or travel		
	, , , , , , , , , , , , , , , , , , , ,		
8	Patents planned, issued or	X None	
J	pending		
	L0		
0	Daubiainabian au - Data	V None	
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	X None	
Ple	ase summarize the above o	onflict of interest in the fo	llowing box:
_			
	None.		
L			
Ple	ase place an "X" next to the	e following statement to in	ndicate your agreement:

Da	Date:July. 8, 2021			
Yo	Your Name: Qun Zhao_			
Ma	Manuscript Title:Neoadjuvant intraper	itoneal and	systemic paclitaxel combined with apatinib and S-1	
ch	chemotherapy for conversion therapy in gast	ric cancer pa	atients with positive exfoliative cytology: a prospective	<u> </u>
stı	study			
Ma	Manuscript number (if known):JGO-21-3	75		
rel pa to rel	related to the content of your manuscript. "Reparties whose interests may be affected by the to transparency and does not necessarily ind relationship/activity/interest, it is preferable	Related" mean ne content o icate a bias. that you do	-	
	manuscript only.	•		
to	• •	ould declare	defined broadly. For example, if your manuscript perta all relationships with manufacturers of antihypertensi the manuscript.	
	In item #1 below, report all support for the withe time frame for disclosure is the past 36 m	-	d in this manuscript without time limit. For all other it	ems
	Name all entiti	es with	Specifications/Comments	
	whom you have	e this	(e.g., if payments were made to you or to your	
	relationship or		institution)	
	none (add row	s as		
	needed)			

		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

_			
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
	testimony		
7	Support for attending	X None	
	meetings and/or travel		
	, , , , , , , , , , , , , , , , , , , ,		
8	Patents planned, issued or	X None	
J	pending		
	L		
0	Daubiainabian au - Data	V None	
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	X None	
Ple	ase summarize the above o	onflict of interest in the fo	llowing box:
_			
	None.		
L			
Ple	ase place an "X" next to the	e following statement to in	ndicate your agreement: